|Product Name||ZP 1609|
|Synonyms||GAP-134;(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid;Danegaptide;GAP 134; ZP-1609|
|Description||ZP 1609, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, which is confirmed in phase I clinical trials. It is used for the treatment of atrial fibrillation. It improves conduction and reduces atrial fibrillation or flutter in the canine sterile pericarditis model. It prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. It showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. It was developed by Zealand Pharma and was termination in Clinical phase II.|
|Quality Standard||In-house standard|
|Targets||Gap Junction Protein|
|Current Developer||ZP 1609 was developed by Zealand Pharma and was termination in Clinical phase II.|
ZP 1609, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a ph...
ZP 1609 Hydrochloride
ZP 1609 Hydrochloride is the hydrochloride form of ZP 1609, which is a small modified dipeptide and has been identified as a potent and selective second generat...
Gap 27, a peptide derived from connexin 43, is a gap junction inhibitor.